Experimental group:Hetrombopag

3 trials

Sponsors

The First Affiliated Hospital of Zhejiang University Medical College, The Affiliated Cancer Hospital of Shandong First Medical University, The Affliated Changzhou No. 2 People’s Hospital of Nanjing Medical University

Conditions

Chemotherapy-related thrombocytopeniaPatients with a confirmed diagnosis of advanced gastric cancer, esophageal cancer, or colorectal cancer.myelodysplastic syndromes

Phase 2

A ClinicaI Investigation on the Safety and Effectiveness of Hetrombopag for the Secondary Prevention of Thrombocytopenia Associated with the Treatment of Lymphoma

Active, not recruitingChiCTR2400094077

The Affiliated Cancer Hospital of Shandong First Medical UniversityChemotherapy-related thrombocytopenia

Start: 2024-12-20Updated: 2025-01-06

Unknown Phase

A Prospective, Single-arm, Multicenter Clinical Study of the Efficacy and Safety of Hetrombopag in the Treatment of Adults with Low-Risk Myelodysplastic Syndrome and Thrombocytopenia

RecruitingChiCTR2300068232

The First Affiliated Hospital of Zhejiang University Medical Collegemyelodysplastic syndromes

Start: 2024-05-15Updated: 2024-11-18

Hetrombopag combined with dexamethasone for the treatment of severe recurrent chemotherapy-induced thrombocytopenia (CTIT) in gastrointestinal tumors

Active, not recruitingChiCTR2600125575

The Affliated Changzhou No. 2 People’s Hospital of Nanjing Medical UniversityPatients with a confirmed diagnosis of advanced gastric cancer, esophageal cancer, or colorectal cancer.

Start: 2026-06-01Updated: 2026-06-01

Related Papers

Hetrombopag for the treatment of lower-risk myelodysplastic syndromes with thrombocytopenia: A prospective, single-arm, multicenter study

Blood2025-11-03